Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET A receptor antagonism
Author Information
Author(s): Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos P B, Burnstock G, Taylor I
Primary Institution: The Royal Free and University College Medical School
Hypothesis
What role does endothelin-1 (ET-1) play in colorectal cancer?
Conclusion
The study found that ET-1 levels are higher in colorectal cancer patients and that blocking ET A receptors can reduce tumor growth.
Supporting Evidence
- ET-1 plasma levels were significantly increased in patients with primary tumors and metastases compared to controls.
- Strong expression of ET-1 was found in cancer tissues, unlike normal colon tissues.
- Treatment with the ET A antagonist led to a significant reduction in liver tumor weights in a rat model.
Takeaway
This study shows that a substance called ET-1 is higher in people with colorectal cancer, and blocking its effects can help shrink tumors.
Methodology
The study measured ET-1 levels in patients and assessed the effect of ET A receptor antagonists in a rat model.
Participant Demographics
Patients included 22 controls, 39 with primary colorectal cancer, and 26 with liver metastases.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website